NCT02911142 2025-07-28Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaNational Institutes of Health Clinical Center (CC)Phase 1/2 Active not recruiting17 enrolled 21 charts
NCT05201248 2025-01-07A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaGenmabPhase 1/2 Active not recruiting49 enrolled
NCT03677141 2024-12-18A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaHoffmann-La RochePhase 1/2 Completed117 enrolled 26 charts
NCT02481310 2022-02-21Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaNorthwestern UniversityPhase 1/2 Unknown38 enrolled 12 charts
NCT00379574 2013-03-15Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCLAsan Medical CenterPhase 1/2 Completed49 enrolled 8 charts